Michael Burkes Brophy Sells 1,523 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,523 shares of the firm’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total value of $139,171.74. Following the completion of the transaction, the chief financial officer now owns 73,039 shares in the company, valued at approximately $6,674,303.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total value of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The shares were sold at an average price of $88.36, for a total value of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The stock was sold at an average price of $70.03, for a total value of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total value of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The stock was sold at an average price of $65.09, for a total value of $210,566.15.

Natera Price Performance

Shares of NASDAQ NTRA opened at $91.50 on Thursday. The firm has a market capitalization of $11.05 billion, a P/E ratio of -24.29 and a beta of 1.37. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The stock’s 50-day simple moving average is $86.85 and its two-hundred day simple moving average is $66.82. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $98.82.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The business had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. As a group, equities analysts anticipate that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NTRA. Sanford C. Bernstein upgraded Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a report on Friday, April 5th. BTIG Research upped their price target on Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research report on Friday, December 29th. The Goldman Sachs Group upped their price target on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, April 15th. Stephens reaffirmed an “overweight” rating and set a $78.00 price target on shares of Natera in a research report on Tuesday, January 30th. Finally, StockNews.com cut Natera from a “hold” rating to a “sell” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.40.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in NTRA. Allspring Global Investments Holdings LLC increased its position in shares of Natera by 28.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock valued at $45,111,000 after purchasing an additional 159,993 shares during the last quarter. Cerity Partners LLC increased its position in shares of Natera by 1,043.3% during the 4th quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock valued at $5,664,000 after purchasing an additional 82,514 shares during the last quarter. WCM Investment Management LLC increased its position in shares of Natera by 101.2% during the 4th quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock valued at $9,058,000 after purchasing an additional 73,419 shares during the last quarter. Aigen Investment Management LP bought a new position in shares of Natera during the 3rd quarter valued at about $223,000. Finally, Sei Investments Co. increased its position in shares of Natera by 33.4% during the 3rd quarter. Sei Investments Co. now owns 374,004 shares of the medical research company’s stock valued at $16,550,000 after purchasing an additional 93,556 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.